Article
Circulating tumor DNA in liquid biopsy: Current diagnostic limitation
19 Apr 2024
Abstract excerpt
With the rapid development of science and technology, cell-free DNA (cfDNA) is rapidly becoming an important biomarker for tumor diagnosis, monitoring and prognosis, and this cfDNA-based liquid biopsy technology has great potential to become an important part of precision medicine. cfDNA is the total amount of free DNA in the systemic circulation, including DNA fragments derived from tumor cells and all other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
